In the current multicenter clinical study, SDC2/TFPI2-joined detection demonstrated an overall sensitivity for all CRCs at 96.6% with the specificity at 96.4%, and the sensitivity for adenoma was as high as 80%, in contrast to the sensitivity of 30% for adenoma by the fecal occult blood test with high-sensitivity guaiac (gFOBT), or the fecal immunochemical test (FIT) (Graser et al., 2009), which are non-invasive detection methods that are most commonly used in clinical practice at present. This evidence concerns the gene TFPI2 and adenoma.